Advances in new research on the bioimmune anti-cancer drug YS-ON-001

Today, the company, the http://Pharmaceutical(http://Limited,announced http://
that the company's immuno-cancerdrug(http://YS-ON-001 has made new research progress, with excellent tumor treatment resultsthis discovery was made on animal liver cancer models, through the partial injection of tumor yS-ON-001, showing significant tumor inhibition effect, and by theproduct(http://caused by the tumor micro-environmental impact of the study, further confirmed the anti-cancer mechanism of the productas a class of therapeutic biologics, YS-ON-001's clinical application has been formally accepted by the National FoodMedicines(http:// Regulatory Agency Drug Review Center (CDE) and has been awarded by the U.S Food and Drug Administration (
FDA (http:// ) for the treatment of pancreatic and liver cancer orphan drugs YS-ON-001 is currently in the clinical research phase in several countries and has been the first to obtain the product code of the Ministry of Health of Cambodia (product trademark, Yivyka ™) 　　YS-ON-001 can improve the anti-tumor cell's anti-killer function of impregnated lymphocytes and natural killer cells while weakening the immunosuppressive effect of tumor microenvironment, and has attractive broad spectrum in anti-solid tumors, showing excellent efficacy and safety in breast cancer, lung cancer, liver cancer, pancreatic cancer, prostate cancer and other solid tumor treatment, which is also an important breakthrough for Chinese scientists in immunotherapy treatment of tumors